Advertisement

Biologics

Bone Biologics and the University of California Los Angeles plan to begin their joint venture clinical trial testing the efficacy of their bone graft substitute treatment for spinal fusion, trauma, osteoporosis and other bone-related indications in 2023.

Advertisement

Bone Biologics, which focuses on spinal orthobiologics, announced its underwritten public offering for $5.1 million total.

Advertisement